Literature DB >> 24419257

Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?

Michelle L O'Donoghue1.   

Abstract

The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) inhibitor, in patients with an acute coronary syndrome was terminated prematurely owing to futility and a signal towards harm. Despite these discouraging results, therapies that target inflammation to modify pathways in atherogenesis remain an area of active investigation.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24419257     DOI： 10.1038/nrcardio.2013.220

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.

Authors:  G G Schwartz; A G Olsson; M D Ezekowitz; P Ganz; M F Oliver; D Waters; A Zeiher; B R Chaitman; S Leslie; T Stern
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

Review 2.  Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers.

Authors:  Ziad Mallat; Gérard Lambeau; Alain Tedgui
Journal:  Circulation       Date:  2010-11-23       Impact factor: 29.690

3.  The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.

Authors:  Vladimír Džavík; Shahar Lavi; Kevin Thorpe; Paul M Yip; Sylvain Plante; Douglas Ing; Christopher B Overgaard; Mark D Osten; Julie Lan; Kim Robbins; Steven E Miner; Eric M Horlick; Warren J Cantor
Journal:  Circulation       Date:  2010-11-22       Impact factor: 29.690

Review 4.  Phospholipase A2 enzymes and the risk of atherosclerosis.

Authors:  Robert S Rosenson; Eva Hurt-Camejo
Journal:  Eur Heart J       Date:  2012-07-15       Impact factor: 29.983

5.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

6.  Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.

Authors:  Daisuke Fujioka; Yukio Saito; Tsuyoshi Kobayashi; Toshiaki Yano; Hideo Tezuka; Yoshikazu Ishimoto; Noriko Suzuki; Yasunori Yokota; Takamitsu Nakamura; Jyun-ei Obata; Masaki Kanazawa; Ken-ichi Kawabata; Kohji Hanasaki; Kiyotaka Kugiyama
Journal:  Circulation       Date:  2008-05-27       Impact factor: 29.690

7.  The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).

Authors:  Zory Shaposhnik; Xuping Wang; Joaquim Trias; Heather Fraser; Aldons J Lusis
Journal:  J Lipid Res       Date:  2008-11-21       Impact factor: 5.922

8.  Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.

Authors:  Stephen J Nicholls; John J P Kastelein; Gregory G Schwartz; Dianna Bash; Robert S Rosenson; Matthew A Cavender; Danielle M Brennan; Wolfgang Koenig; J Wouter Jukema; Vijay Nambi; R Scott Wright; Venu Menon; A Michael Lincoff; Steven E Nissen
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

9.  Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.

Authors:  Michael V Holmes; Tabassome Simon; Holly J Exeter; Lasse Folkersen; Folkert W Asselbergs; Montse Guardiola; Jackie A Cooper; Jutta Palmen; Jaroslav A Hubacek; Kathryn F Carruthers; Benjamin D Horne; Kimberly D Brunisholz; Jessica L Mega; Erik P A van Iperen; Mingyao Li; Maarten Leusink; Stella Trompet; Jeffrey J W Verschuren; G Kees Hovingh; Abbas Dehghan; Christopher P Nelson; Salma Kotti; Nicolas Danchin; Markus Scholz; Christiane L Haase; Dietrich Rothenbacher; Daniel I Swerdlow; Karoline B Kuchenbaecker; Eleonora Staines-Urias; Anuj Goel; Ferdinand van 't Hooft; Karl Gertow; Ulf de Faire; Andrie G Panayiotou; Elena Tremoli; Damiano Baldassarre; Fabrizio Veglia; Lesca M Holdt; Frank Beutner; Ron T Gansevoort; Gerjan J Navis; Irene Mateo Leach; Lutz P Breitling; Hermann Brenner; Joachim Thiery; Dhayana Dallmeier; Anders Franco-Cereceda; Jolanda M A Boer; Jeffrey W Stephens; Marten H Hofker; Alain Tedgui; Albert Hofman; André G Uitterlinden; Vera Adamkova; Jan Pitha; N Charlotte Onland-Moret; Maarten J Cramer; Hendrik M Nathoe; Wilko Spiering; Olaf H Klungel; Meena Kumari; Peter H Whincup; David A Morrow; Peter S Braund; Alistair S Hall; Anders G Olsson; Pieter A Doevendans; Mieke D Trip; Martin D Tobin; Anders Hamsten; Hugh Watkins; Wolfgang Koenig; Andrew N Nicolaides; Daniel Teupser; Ian N M Day; John F Carlquist; Tom R Gaunt; Ian Ford; Naveed Sattar; Sotirios Tsimikas; Gregory G Schwartz; Debbie A Lawlor; Richard W Morris; Manjinder S Sandhu; Rudolf Poledne; Anke H Maitland-van der Zee; Kay-Tee Khaw; Brendan J Keating; Pim van der Harst; Jackie F Price; Shamir R Mehta; Salim Yusuf; Jaqueline C M Witteman; Oscar H Franco; J Wouter Jukema; Peter de Knijff; Anne Tybjaerg-Hansen; Daniel J Rader; Martin Farrall; Nilesh J Samani; Mika Kivimaki; Keith A A Fox; Steve E Humphries; Jeffrey L Anderson; S Matthijs Boekholdt; Tom M Palmer; Per Eriksson; Guillaume Paré; Aroon D Hingorani; Marc S Sabatine; Ziad Mallat; Juan P Casas; Philippa J Talmud
Journal:  J Am Coll Cardiol       Date:  2013-07-31       Impact factor: 24.094
  9 in total
  1 in total

Review 1.  Human Group IIA Phospholipase A2-Three Decades on from Its Discovery.

Authors:  Kieran F Scott; Timothy J Mann; Shadma Fatima; Mila Sajinovic; Anshuli Razdan; Ryung Rae Kim; Adam Cooper; Aflah Roohullah; Katherine J Bryant; Kasuni K Gamage; David G Harman; Fatemeh Vafaee; Garry G Graham; W Bret Church; Pamela J Russell; Qihan Dong; Paul de Souza
Journal:  Molecules       Date:  2021-11-30       Impact factor: 4.411
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.